{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000058","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-05-14T11:53:38+00:00","discovered_at":"2026-05-14T11:55:00.441194+00:00","generated_at":"2026-05-14T11:55:37.869719+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M","bullets":["Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.","Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.","Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.","Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.","Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000058","json":"https://secwatch.observer/filing/0001730463-26-000058.json","markdown":"https://secwatch.observer/filing/0001730463-26-000058.md","text":"https://secwatch.observer/filing/0001730463-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/0001730463-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autl-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:55:37.869719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d8342ced652f0e3da6286fb24818202d790e142","claim":"Autolus Therapeutics plc reported first quarter ended March 31, 2026 results: revenue $26.2 million. Guidance reaffirmed.","evidence_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/0001730463-26-000058-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$26.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}